Infectious Disease & Vaccines
| 3 min read
Gut microbes can protect or sensitize each other to drugs, even to non-antibiotics.
| 3 min read
A new vaccination schedule pumps up the immune response to human immunodeficiency virus, overcoming a barrier that has frustrated vaccine designers.
| 2 min read
As scientific output grows, the risk of a promising drug getting lost increases, but advances in artificial intelligence and machine learning may prevent that.
| 3 min read
Bacteria’s constant interaction with viruses has led them to evolve antiviral strategies.
| 2 min read
Rhinoviruses, the main cause of the common cold, are unique among respiratory viruses.
| 3 min read
Doctors have been treating bacterial vaginosis with the same antibiotic for decades. This fatty acid could change that.
| 3 min read
Engineered peptides that mimic molecules of the innate immune system act synergistically with available drugs to treat Candida albicans in an animal model.
| 4 min read
Microparticle injections containing an immunomodulator protein inhibited bone loss and promoted repair in a mouse model of periodontal disease.
| 4 min read
Merck researchers developed an effective vaccine against pneumococcal diseases.
| 3 min read
In a mix of innovation and accident, researchers developed a new antibiotic that has broad efficacy across Gram-positive bacteria.
| 4 min read
Proteins from intracellular pathogens can help expel drugs delivered by macrophages.
| 9 min read
There is no vaccine against this parasitic worm infection, but rhesus macaques’ unique immune system has brought the prospect of a vaccine closer than ever.
| 4 min read
Scientists developed an unprecedented chemical tool to visualize sphingomyelin and sphingomyelinase activity during a chlamydia infection.
| 3 min read
Organ-on-a-chip technology can replicate the cervix microenvironment in bacterial vaginosis.
| 3 min read
Bacteria can invade colorectal cancer tumors, leading to worse disease outcomes. Oxygen — or lack thereof — plays a vital role in this interaction.
| 4 min read
An agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing.
| 3 min read
Nonhuman primates treated with the mRNA vaccine recovered faster and had less severe disease than those given available mpox vaccines.
| 7 min read
A new model predicts how well maternal vaccines protect babies from Group B Streptococcus, propelling much needed shots through late-stage clinical trials.
| 3 min read
Plectasin forms dense structures on bacterial membranes by binding to unique lipids in bacterial cell walls.
| 4 min read
Researchers uncovered the structure of the measles fusion glycoprotein and identified a neutralizing antibody capable of decreasing its virulence.
| 8 min read
Biofilms render most antibiotics ineffective, but ultrasound may be the key to clearing these chronic infections.
| 3 min read
Placental macrophages play a role in the immune response against pathogens.
Available on Demand
Organic molecules with novel biological properties offer new ways to eliminate multidrug-resistant bacteria.
Page 1 of 212 - 4225 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Touchlight and GSK sign license agreement for use of enzymatic dbDNA production technology for mRNA manufacturing
An agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing.
Turbocharging mRNA vaccine development
Cell-free gene synthesis technology offers a quick, reliable route to creating vital mRNA vaccines and therapeutics.
Explained: How do scientists make mRNA in vitro?
In vitro transcription lays the foundation for recent advances in mRNA vaccines and therapeutics.
